Tezepelumab was linked to significantly reduced nasal polyp size and nasal congestion vs placebo in adults with severe CRSwNP.

A drug billed by Sanofi as a successor to its blockbuster inflammation and immunology blockbuster Dupixent is being prepared for phase 3 trials in asthma – even though it missed the mark in a midstage ...

Sanofi’s respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPDNew phase 2 data for amlitelimab show ...

Dupixent approved as the first-ever biologic medicine in Japan for patients with COPDFollowing recent approvals in the EU, China, and the US, ...

Please provide your email address to receive an email when new articles are posted on . The need for systemic corticosteroids fell by 88%, and the need for surgery fell by 98%. Nasal polyp and ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

In addition to COPD, Dupixent is approved in Japan in certain patients with atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), prurigo nodularis, and chronic ...

Simultaneously, the three regulators are also reviewing a second potential indication for depemokimab as an add-on therapy for chronic rhinosinusitis with nasal polyps (CRSwNP). GSK has said ...

Three new drug applications of Stapokibart for the treatment of moderate-to-severe atopic dermatitis (AD) in adults, chronic rhinosinusitis with nasal polyposis (CRSwNP) and seasonal allergic ...

The China National Medical Products Administration (NMPA) has approved GSK’s Nucala (mepolizumab) as an add-on treatment with intranasal corticosteroids to treat chronic rhinosinusitis with ...